![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Clinerion has signed a Memorandum of Understanding with the P-HIS Development Group of Korea University Medical Center (KUMC) to support the KUMC’s activities in developing a patient data platform in the Republic of Korea, in particular for precision medicine.
Clinerion’s contribution will involve implementation and use of its Patient Network Explorer solution.
The government of the Republic of Korea has created a National Key Project dedicated to precision medicine, involving both the Ministry of Science and IT and the Ministry of Health and Welfare. The KUMC leads this project, with twin pillars being the development of a universal common data model (as part of the Observational Health Data Sciences and Informatics (OHDSI) consortium) and a precision medicine cloud HIS platform (P-HIS). Both pillars will support the provision of a patient data platform which can be used for analysis for precision medicine.
The Clinerion Patient Network Explorer (formerly PRS) enables the query of patient data from partner hospitals without compromising patient data privacy and without the data needing to leave the hospital IT infrastructure. The results of the queries are seen only as counts of patients matching inclusion/exclusion criteria; however, partner hospitals have a method of identifying matching anonymized patients for enrollment in clinical trials via Clinerion’s proprietary “Anonymized Identification” technology.
“Clinerion’s established approach fits very well with the direction we have been pursuing,” says Professor Sang-Heon Lee, Head of Korea Precision Medicine Development Group and Professor at Korea University Medical Center. “We are very pleased with the reliability and scalability of their solution. As South Korea has very strict patient privacy regulations, we are also happy to see their in-built protections for privacy.”
“The Republic of Korea offers a world-class stage for Clinerion which pushes the boundaries of technological possibility in secure patient data analytics,” says Ian Rentsch, CEO of Clinerion. “We are thrilled that KUMC offers us this chance to show the capabilities of Patient Network Explorer.”
About Clinerion
Clinerion enables early patient access to innovative treatments through real-patient data solutions for clinical trial patient recruitment, real-world evidence, and market access. Clinerion’s Patient Network Explorer accelerates clinical research by radically improving the efficiency and effectiveness of trial recruitment. Clinerion’s key patient data services include data-driven protocol optimization, site feasibility evaluation and patient identification. Clinerion’s solutions allow member hospitals to participate in leading-edge, industry-sponsored trials and save time in patient recruitment. They enable pharmaceutical companies to gain time and save costs by streamlining operations and leveraging strategic intelligence. Clinerion’s proprietary Big Data analytics technologies leverage real-time data from electronic health records which remain under the full control of participating hospitals. Clinerion is a global data technology service company headquartered in Switzerland. Clinerion’s solutions comply with international patient privacy and data security regulations.
Clinerion website: www.clinerion.com
Clinerion’s Patient Network Explorer: www.clinerion.com/index/OverviewOurSolutions/Clineriontechnologysolution
